KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Interest Expenses for 13 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 8.17% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Dec 2025, changed 0.17% year-over-year, with the annual reading at $18.1 million for FY2025, 0.17% changed from the prior year.
  • Interest Expenses for Q4 2025 was $4.9 million at Halozyme Therapeutics, up from $4.3 million in the prior quarter.
  • The five-year high for Interest Expenses was $7.5 million in Q3 2022, with the low at $1.8 million in Q2 2021.
  • Average Interest Expenses over 5 years is $4.0 million, with a median of $4.5 million recorded in 2023.
  • The sharpest move saw Interest Expenses plummeted 64.99% in 2021, then soared 328.39% in 2022.
  • Over 5 years, Interest Expenses stood at $2.1 million in 2021, then surged by 122.38% to $4.6 million in 2022, then rose by 14.22% to $5.2 million in 2023, then dropped by 13.03% to $4.5 million in 2024, then increased by 8.17% to $4.9 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $4.9 million, $4.3 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.